ATE228142T1 - Verbindungen und verfahren zur inhibierung der verbreitung der hiv - Google Patents

Verbindungen und verfahren zur inhibierung der verbreitung der hiv

Info

Publication number
ATE228142T1
ATE228142T1 AT95111359T AT95111359T ATE228142T1 AT E228142 T1 ATE228142 T1 AT E228142T1 AT 95111359 T AT95111359 T AT 95111359T AT 95111359 T AT95111359 T AT 95111359T AT E228142 T1 ATE228142 T1 AT E228142T1
Authority
AT
Austria
Prior art keywords
hiv
inhibiting
spread
compounds
methods
Prior art date
Application number
AT95111359T
Other languages
English (en)
Inventor
Thomas B Ryder
Theodore J Kwoh
Original Assignee
Gen Probe Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Gen Probe Inc filed Critical Gen Probe Inc
Application granted granted Critical
Publication of ATE228142T1 publication Critical patent/ATE228142T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1131—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against viruses
    • C12N15/1132—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against viruses against retroviridae, e.g. HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/31—Chemical structure of the backbone
    • C12N2310/315—Phosphorothioates

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Virology (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • AIDS & HIV (AREA)
  • Biochemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Plant Pathology (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Veterinary Medicine (AREA)
  • Microbiology (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Oncology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Communicable Diseases (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Saccharide Compounds (AREA)
AT95111359T 1994-07-19 1995-07-19 Verbindungen und verfahren zur inhibierung der verbreitung der hiv ATE228142T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US08/277,857 US5733781A (en) 1994-07-19 1994-07-19 Oligonucleotides and methods for inhibiting propagation of human immunodeficiency virus

Publications (1)

Publication Number Publication Date
ATE228142T1 true ATE228142T1 (de) 2002-12-15

Family

ID=23062654

Family Applications (1)

Application Number Title Priority Date Filing Date
AT95111359T ATE228142T1 (de) 1994-07-19 1995-07-19 Verbindungen und verfahren zur inhibierung der verbreitung der hiv

Country Status (9)

Country Link
US (1) US5733781A (de)
EP (1) EP0697414B1 (de)
JP (1) JP3307944B2 (de)
KR (1) KR970704768A (de)
AT (1) ATE228142T1 (de)
AU (1) AU699233B2 (de)
CA (1) CA2194398A1 (de)
DE (1) DE69528867D1 (de)
WO (1) WO1996002557A1 (de)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2279669A1 (en) * 1995-12-15 1997-06-16 Enzo Therapeutics, Inc. Property effecting and/or property exhibiting constructs for the expression of non-native nucleic acid processing components for therapeutic and diagnostic uses
US6776986B1 (en) 1996-06-06 2004-08-17 Novartis Ag Inhibition of HIV-1 replication by antisense RNA expression
DE69727984T2 (de) * 1996-07-09 2005-01-05 Canji, Inc., San Diego Verfahren zur messung viraler infektivität
US5962665A (en) * 1997-06-16 1999-10-05 Abbott Laboratories Nucleic acid primers and probes for detecting HIV-1 and HIV-2
US7244570B2 (en) * 1998-08-04 2007-07-17 Luminex Molecular Diagnostics, Inc. Methods and compositions for modulating “marginally indiscriminant” hybridizations
US6867037B1 (en) * 1998-08-10 2005-03-15 Meiji Dairies Corp. High level secretory expression system of intact MK family protein
DE19850186A1 (de) * 1998-10-30 2000-05-25 Roche Diagnostics Gmbh Neue Primer und Sonden zum Nachweis von HIV
AU2221600A (en) 1998-12-31 2000-07-31 Chiron Corporation Improved expression of hiv polypeptides and production of virus-like particles
EP1141314A2 (de) 1998-12-31 2001-10-10 Chiron Corporation Für antigene polypeptide des hiv type c kodierende polynukleotide, entsprechende polypeptide und verwendungen davon
AU3219400A (en) 1999-02-03 2000-08-25 Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services, The Methods and reagents for molecular detection of hiv-1 groups m, n and
KR20020069627A (ko) * 2001-02-27 2002-09-05 동부한농화학 주식회사 육환의 아자슈거를 가진 뉴클레오타이드 유도체를 포함한포스포로티오에이트 올리고뉴클레오타이드 및 이들의에이즈 치료제로서의 새로운 용도
AU2002320314A1 (en) 2001-07-05 2003-01-21 Chiron, Corporation Polynucleotides encoding antigenic hiv type c polypeptides, polypeptides and uses thereof
US20030170614A1 (en) 2001-08-31 2003-09-11 Megede Jan Zur Polynucleotides encoding antigenic HIV type B polypeptides, polypeptides and uses thereof
US6852491B2 (en) * 2001-09-04 2005-02-08 Abbott Laboratories Amplification and detection reagents for HIV-1
US20050222068A1 (en) * 2003-10-23 2005-10-06 Mourich Dan V Method and antisense composition for selective inhibition of HIV infection in hematopoietic cells
US20060205070A1 (en) * 2004-01-13 2006-09-14 The Government Of The Usa, As Represented By The Secretary, Department Of Health And Human Services HIV TEV compositions and methods of use
US20060240032A1 (en) * 2005-03-31 2006-10-26 Hinrichs David J Immunomodulating compositions and methods for use in the treatment of human autoimmune diseases
EP2121984A2 (de) * 2007-03-16 2009-11-25 454 Life Sciences Corporation System und verfahren zur erkennung von hiv-arzneiresistenten varianten
US8592386B2 (en) * 2008-12-17 2013-11-26 Sarepta Therapeutics, Inc. Antisense compositions and methods for modulating contact hypersensitivity or contact dermatitis
NL2010579C2 (nl) 2013-04-05 2014-10-07 Thomas Regout Internat B V Anti-kantelsamenstel voor een reeks van laden in een gereedschapskast.

Family Cites Families (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5023243A (en) * 1981-10-23 1991-06-11 Molecular Biosystems, Inc. Oligonucleotide therapeutic agent and method of making same
GB8423659D0 (en) * 1984-09-19 1984-10-24 Pasteur Institut Cloned dna sequences
NZ209840A (en) * 1983-10-17 1988-11-29 Kaji Akira A method of inhibiting viral propagation by hybridising dna with the viral rna thus blocking its action
US4738922A (en) * 1984-05-25 1988-04-19 Dana Farber Cancer Institute Trans-acting transcriptional factors
IL79391A (en) * 1985-08-14 1994-06-24 Hughes Aircraft Co Non-spherical patch with a stepped key and a display system that uses it
US4752565A (en) 1986-04-07 1988-06-21 The United States Of America As Represented By The Department Of Health And Human Services Cell line producing AIDS viral antigens without producing infectious virus particles
US4806463A (en) * 1986-05-23 1989-02-21 Worcester Foundation For Experimental Biology Inhibition of HTLV-III by exogenous oligonucleotides
US5264423A (en) * 1987-03-25 1993-11-23 The United States Of America As Represented By The Department Of Health And Human Services Inhibitors for replication of retroviruses and for the expression of oncogene products
IL86832A (en) * 1987-06-22 2002-09-12 Medeva Holdings Bv A recombinant DNA molecule containing a nucleotide sequence of part of the region encoding HBV pre-1s, an immunogenic particle containing multiple peptide monomers containing a pre-s1 epitope and pharmaceutical preparations containing it
US5110802A (en) * 1987-07-14 1992-05-05 City Of Hope Oligonucleotide phosphonates and method of inhibiting a human immunodeficiency virus in vitro utilizing said oligonucleotide phosphonates
WO1989002476A1 (en) 1987-09-21 1989-03-23 Ml Technology Ventures, L.P. Homogeneous protection assay
IL89993A0 (en) * 1988-04-25 1989-12-15 Phillips Petroleum Co Expression of the hiv 24kda gag protein in methylotrophic yeasts
US5449769A (en) 1989-03-06 1995-09-12 Gen-Probe Incorporated Method and reagent for sulfurization of organophosphorous compounds
ES2275451T3 (es) * 1989-06-02 2009-02-16 Institut Pasteur Secuencias nucleotidicas procedentes del genoma de los retrovirus del tipo vih-1,vih-2 y siv, y sus aplicaciones especialmente para la amplificacion de los genomas de estos retrovirus y para el diagnostico in vitro de las infecciones debidas a estos virus.
US5144019A (en) * 1989-06-21 1992-09-01 City Of Hope Ribozyme cleavage of HIV-I RNA
ATE184321T1 (de) * 1990-01-10 1999-09-15 Chiron Diagnostics Corp Dns-abhängige rns-polymerase-transkripte als reportermoleküle zur signalverstärkung in nukleinsäure-hybridisierungsuntersuchungen
US5166195A (en) * 1990-05-11 1992-11-24 Isis Pharmaceuticals, Inc. Antisense inhibitors of the human immunodeficiency virus phosphorothioate oligonucleotides
ES2124231T3 (es) 1990-10-26 1999-02-01 Genta Inc Procedimiento mejorado para sintesis de oligomeros.
WO1992016180A2 (en) * 1991-03-13 1992-10-01 Siska Diagnostics, Inc. Detection of 3'-azido-3'-deoxythymidine resistance
FR2677039B1 (fr) * 1991-05-31 1994-09-09 Cis Bio Int Oligonucleotides, utilisables comme reactifs pour la detection in vitro des infections a retrovirus de type hiv et procede de detection de retrovirus de type hiv.
US5226326A (en) * 1991-05-31 1993-07-13 Environmental Stress Screening Corp. Vibration chamber
ES2267094T3 (es) * 1991-12-23 2007-03-01 Novartis Vaccines And Diagnostics, Inc. Conjunto de sondas de vih para su uso en ensayos de hibridacion en sandwich en fase de disolucion.
US5585479A (en) * 1992-07-24 1996-12-17 The United States Of America As Represented By The Secretary Of The Navy Antisense oligonucleotides directed against human ELAM-I RNA
FI951600A7 (fi) * 1992-10-05 1995-05-10 Hybridon Inc Terapeuttinen HIV:n vastainen oligonukleotidi ja lääkeaine
JP4108118B2 (ja) * 1993-03-26 2008-06-25 ジェン−プローブ・インコーポレイテッド ヒト・免疫不全ウイルス１型の検出
CA2647030C (en) 2006-03-09 2016-10-25 3M Innovative Properties Company Device for dispensing material
CN101689633A (zh) 2007-05-08 2010-03-31 加利福尼亚大学董事会 高放电倍率锂离子电池
US8803361B2 (en) 2011-01-19 2014-08-12 Schneider Electric It Corporation Apparatus and method for providing uninterruptible power
US9202037B2 (en) 2012-06-08 2015-12-01 General Electric Company System and method for using machine readable code to commission device applications

Also Published As

Publication number Publication date
EP0697414B1 (de) 2002-11-20
CA2194398A1 (en) 1996-02-01
AU699233B2 (en) 1998-11-26
WO1996002557A1 (en) 1996-02-01
US5733781A (en) 1998-03-31
DE69528867D1 (de) 2003-01-02
EP0697414A1 (de) 1996-02-21
JP3307944B2 (ja) 2002-07-29
AU3135495A (en) 1996-02-16
JPH10501421A (ja) 1998-02-10
KR970704768A (ko) 1997-09-06

Similar Documents

Publication Publication Date Title
DE69528867D1 (de) Verbindungen und Verfahren zur Inhibierung der Verbreitung der HIV
DE69432635D1 (de) Oligonukleotide mit wirkung gegen den menschlichen immunodefiziens-virus
ATE289519T1 (de) Zusammensetzungen und verfahren zur behandlung von hepatitis c virus-bedingten erkrankungen
ATE232095T1 (de) Verbindungen und verfahren zur inhibierung von hiv- und verwandten viren
DE69830751D1 (de) Polyaromatische Verbindungen zur Behandlung von Herpes-Infektionen
DE69334250D1 (de) Verfahren und Intermediate zur Herstellung von retroviralen Proteasehemmern
FI946066L (fi) Hepatiitti-C viruksen genotyyppien uudet sekvenssit ja niiden käyttö terapeuttisina ja diagnostisina aineina
GEP20104960B (en) USE OF [D-MeALa]3-[EtVal]4-CYCLOSPORIN FOR THE TREATMENT OF HEPATITIS C INFECTION AND PHARMACEUTICAL COMPOSITION COMPRISING SAID [D-MeAla]3-[EtVal]4-CYCLOSPORIN
HU901585D0 (en) Method for treatment of viral infections using functional derivatives of icam-1
ATE142873T1 (de) Hemmung einer virusinfektion
ATE312079T1 (de) Nichtnukleoside reverse transkriptase-hemmer zur behandlung von hiv-infektion
IL193148A0 (en) Use of combinations of agents for the preparation of medicaments for treatment of hepatitis b virus
ATE235495T1 (de) 8-arylalkyl- und 8-arylheteroalkyl-5, 11-dihydro- 6h-dipyrido-(3,2-b:2', 3'-e)(1,4)diazepine und ihre verwendung zur vorbeugung oder behandlung von hiv-infektion
DK92788D0 (da) Ny medicinsk anvendelse
DK0604183T3 (da) HIV-protease-inhibitorer anvendelige i behandlingen af AIDS
ATE245444T1 (de) Pharmazeutische zusammensetzung, enthaltend peg- asparaginase, für die behandlung von hiv infektionen
EE03514B1 (et) Ühendite kombinatsioon HIV infektsiooni või AIDS-i raviks, selle kasutamine ja farmatseutiline kompositsioon
ATE148109T1 (de) Hiv-proteaseinhibitoren und ihre verwendung zur behandlung von aids
WO1999051256A3 (en) Use of l-glu-l-trp in the treatment of hiv infection
ATA113492A (de) Mehrfachbeutelsystem zur sterilen behandlung von menschlichen blutkonserven
ATE281173T1 (de) Behandlung einer virusinfektion bei schweinen
UA41338C2 (uk) Спосіб інгібування ретровірусної інфекції, яка викликана вірусом імунодефіциту людини (віл), спосіб інгібування вірусу імунодефіциту людини (віл)
ATE412423T1 (de) Peroxiredoxin-arzneistoffe zur behandlung einer hiv-1-infektion
ATE56878T1 (de) Verfahren und zusammensetzung zur vorbeugung und behandlung von virus-infektionen.
DE19980721D2 (de) CD4-Radioimmunpharmaka zur Behandlung der HIV-Infektion

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties